Textbook/Part 2/Chapter 6

Thoracic and Complex Aortic Disease

Thoracic aortic aneurysms, dissection, and complex aortic pathology including TEVAR

9 sections
42 references
Last updated today

Aortic Dissection Classification

Aortic dissection occurs when an intimal tear allows blood to enter the medial layer, creating a false lumen that propagates along the aorta. It represents one of the most lethal cardiovascular emergencies, with untreated Type A dissection mortality approaching 1% per hour early after symptom onset. (Hagan 2000)πŸ“„ (Erbel 2014)

Stanford Classification

The Stanford system divides dissections based on involvement of the ascending aorta. (Daily 1970)πŸ“„

  • Type A: Any dissection involving the ascending aorta, regardless of the site of primary intimal tear. Requires emergent surgical intervention due to high risk of rupture, tamponade, aortic regurgitation, and coronary malperfusion.
  • Type B: Dissection confined to the descending aorta (distal to the left subclavian artery). Management depends on presence of complications.

Modern classification frameworks from the American Heart Association (AHA), American College of Cardiology (ACC), and the European Society for Vascular Surgery (ESVS) also recognize "Non-A Non-B" dissections, which involve the aortic arch but spare the ascending aorta (Isselbacher 2022)πŸ“„ (Isselbacher 2022) (Wahlgren 2025) (Wanhainen 2026).

DeBakey Classification

The DeBakey system provides anatomic detail based on origin and extent. (De 1965)πŸ“„

  • Type I: Originates in ascending aorta and extends to at least the aortic arch, often to the descending aorta or beyond.
  • Type II: Originates in and is confined to the ascending aorta.
  • Type IIIa: Originates in descending thoracic aorta and extends distally but remains above the diaphragm.
  • Type IIIb: Originates in descending thoracic aorta and extends below the diaphragm.

Table 6.2. Aortic Dissection Classification Systems

Temporal Classification

Timing from symptom onset influences treatment strategy and aortic wall characteristics. Contemporary guidelines define four distinct phases: hyperacute (<24 hours), acute (1–14 days), subacute (15–90 days), and chronic (>90 days) (Isselbacher 2022)πŸ“„ (Isselbacher 2022) (Wahlgren 2025) (Wanhainen 2026). This classification is critical because the aortic wall's friability and the potential for favorable remodeling after thoracic endovascular aortic repair (TEVAR) vary substantially across these timeframes (Erbel 2014) (Wahlgren 2025) (Wanhainen 2026).

Type B Aortic Dissection Management

Type B aortic dissection (TBAD) presents distinct management challenges based on clinical presentation, anatomic extent, and timing, with contemporary practice guided by society guidelines and long-term outcomes studies. (Mac 2022)πŸ“„ (Isselbacher 2022)πŸ“„ (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

Complicated versus Uncomplicated TBAD

Complicated TBAD is defined by one or more of the following high-risk features requiring intervention:

  • Malperfusion syndrome: Visceral, renal, or limb ischemia from true lumen compression or branch vessel involvement
  • Rupture or impending rupture: Hemothorax, periaortic hematoma, rapidly expanding false lumen
  • Refractory hypertension: Despite optimal medical therapy (OMT) with multiple agents
  • Refractory pain: Persistent severe back/chest pain suggesting ongoing dissection
  • Rapid aortic expansion: Greater than 5 mm growth in less than 6 months
  • Maximum aortic diameter exceeding 40 mm during the acute phase (a strong predictor of late complications) (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

Uncomplicated TBAD lacks these features and may be managed with medical therapy alone in the acute setting, though long-term surveillance is mandatory. Recent guidelines from the American Heart Association (AHA), American College of Cardiology (ACC), and the European Society for Vascular Surgery (ESVS) emphasize identifying "high-risk" uncomplicated patients who may benefit from early intervention. (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

Medical Management

All patients with TBAD require aggressive blood pressure and heart rate control to reduce aortic wall stress:

  • Target systolic blood pressure: Less than 120 mmHg
  • Target heart rate: Less than 60 beats per minute to reduce dP/dt

First-line agents include intravenous beta-blockers (esmolol for titratability, labetalol for combined alpha/beta blockade). Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) may be added for rate control. Vasodilators (nicardipine, nitroprusside) address residual hypertension only after adequate heart rate control to prevent reflex tachycardia. (Mac 2022)πŸ“„ (Hiratzka 2010)πŸ“„ (Writing Committee 2022)

Pain control with opioids is essentialβ€”pain drives sympathetic activation and hypertension, creating a destructive feedback loop. Long-term medical therapy includes oral beta-blockers, statins for cardiovascular risk reduction, and aggressive management of hypertension. Smoking cessation is critical given the elevated risk of late aneurysmal degeneration. (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

Endovascular Management: thoracic endovascular aortic repair (TEVAR) for TBAD

Thoracic endovascular aortic repair (TEVAR) has become the preferred intervention for complicated TBAD when anatomy permits. TEVAR seals the primary entry tear, redirecting flow into the true lumen and promoting false lumen thrombosis with favorable aortic remodeling. (Mac 2022)πŸ“„

In stable subacute/chronic TBAD, the INSTEAD randomized trial showed no early survival advantage at 2 years with TEVAR plus optimal medical therapy compared with optimal medical therapy alone, while longer follow-up in INSTEAD-XL demonstrated improved aorta-specific outcomes emerging over time, consistent with a remodeling-mediated benefit. (Nienaber 2009) (Nienaber 2013)πŸ“„

In acute uncomplicated TBAD, randomized data suggest TEVAR can improve aortic remodeling compared with medical therapy alone. (Brunkwall 2014)πŸ“„ Current consensus suggests that for high-risk uncomplicated TBAD, TEVAR should ideally be performed in the subacute phase (2 weeks to 3 months) to maximize remodeling potential while minimizing the risk of retrograde Type A dissection. (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

Indications for TEVAR in TBAD

According to STS/AATS 2022, AHA/ACC 2022, and ESVS 2026 guidance: (Mac 2022)πŸ“„ (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

  • Definite indication: Complicated TBAD (rupture, malperfusion) with suitable anatomy
  • Strong consideration (High-risk features): Uncomplicated TBAD with a primary entry tear >10 mm, entry tear on the outer curvature of the arch, false lumen diameter greater than 22 mm, or total aortic diameter greater than 40 mm
  • May consider: Prophylactic TEVAR in uncomplicated TBAD to reduce late aortic events, particularly in the subacute phase for patients with suitable anatomy and low procedural risk

Technical Considerations

Adequate proximal landing zone (typically β‰₯2 cm of non-dissected aorta) is essential for secure seal. When the entry tear is in the arch, coverage of the left subclavian artery (LSA) may be required. Elective LSA revascularization is recommended (Class I) when coverage compromises antegrade flow to reduce posterior circulation stroke, arm ischemia, and spinal cord ischemia risk. (Matsumura 2009)πŸ“„ (Isselbacher 2022)πŸ“„ (Wanhainen 2026)

Spinal cord protection measures apply when: * Coverage exceeds 20 cm of thoracic aorta * Landing zone is within 2 cm of the celiac artery * Prior abdominal aortic repair exists

The multimodal spinal cord protection bundle includes: cerebrospinal fluid (CSF) drainage (maintain pressure less than 10 mmHg), mean arterial pressure (MAP) greater than 80–90 mmHg, hemoglobin optimization (greater than 10 g/dL), and staged procedures when feasible. (Mac 2022)πŸ“„ (Wanhainen 2026)

Persistent false lumen perfusion and partial thrombosis after TBAD are associated with worse late outcomes and help identify patients who require closer follow-up and may benefit from pre-emptive intervention. (Tsai 2007)πŸ“„

Type A Aortic Dissection

Type A aortic dissection (TAAD) constitutes a surgical emergency. Without intervention, early mortality is high, driven by aortic rupture, cardiac tamponade, acute aortic regurgitation, coronary malperfusion, or stroke. (Hagan 2000)πŸ“„ (Trimarchi 2006) Current guidelines emphasize that management by a multidisciplinary aortic team in high-volume centers is associated with improved survival (Isselbacher 2022) (Isselbacher 2022) (Writing Committee 2022) (Wahlgren 2025).

Clinical Presentation

The classic presentation is sudden, severe "tearing" or "ripping" chest pain radiating to the back. However, presentations vary widely. Clinicians should maintain a high index of suspicion in patients with known genetic predispositions (e.g., Marfan syndrome) or a strong family history of aortic disease (Isselbacher 2022) (Isselbacher 2022) (Writing Committee 2022):

  • Anterior chest pain: Suggests ascending aortic involvement
  • Interscapular pain: Suggests arch or descending extension
  • Syncope: May indicate tamponade, stroke, or severe hypotension
  • Neurologic deficits: Stroke (arch vessel involvement), paraplegia (spinal cord ischemia)
  • Limb ischemia: Pulse deficits from iliac extension or obstruction
  • Abdominal pain: Visceral malperfusion

Physical examination may reveal blood pressure (BP) differential between arms (greater than 20 mmHg), new aortic regurgitation murmur, or signs of tamponade (hypotension, elevated jugular venous pressure (JVP), muffled heart sounds).

Diagnosis

Computed tomography angiography (CTA) is the diagnostic modality of choiceβ€”rapid, widely available, and highly sensitive and specific (Isselbacher 2022) (Writing Committee 2022). Findings include intimal flap, true and false lumens, and extent of dissection. Transesophageal echocardiography (TEE) is an important adjunct, particularly for assessing aortic valve involvement, pericardial effusion, and coronary ostia. (Hiratzka 2010)πŸ“„ (Isselbacher 2022)πŸ“„

Surgical Management

Emergent open surgical repair is the standard of care for TAAD. Initial medical management focuses on aggressive heart rate (HR) and blood pressure (BP) control, typically targeting a systolic blood pressure (SBP) < 120 mmHg and a heart rate < 60 beats per minute (bpm) to reduce aortic wall stress (Isselbacher 2022) (Isselbacher 2022) (Writing Committee 2022) (Writing Committee 2022) (Wahlgren 2025).

  • Ascending aorta replacement: With or without aortic root replacement. In suitable patients, valve-sparing root replacement (VSRR) is preferred over a composite graft (Bentall procedure) to avoid long-term anticoagulation (Isselbacher 2022) (Wahlgren 2025).
  • Hemiarch repair: Replacement of the lesser curvature of the arch under hypothermic circulatory arrest.
  • Total arch replacement: Indicated when the arch is aneurysmal, contains a primary entry tear, or is extensively dissected. This may involve the "frozen elephant trunk" (FET) technique to facilitate future distal repair (Isselbacher 2022) (Wahlgren 2025).

Adjunctive measures include antegrade cerebral perfusion during circulatory arrest to reduce neurologic injury. Contemporary registry data and guideline syntheses support operative repair as the default strategy in eligible patients, with outcomes influenced by malperfusion, age, and center experience. (Trimarchi 2006) (Isselbacher 2022)πŸ“„ (Writing Committee 2022)

Hybrid and Endovascular Approaches

Selected TAAD cases may be candidates for hybrid approaches combining open ascending repair with endovascular arch/descending treatment. Purely endovascular Type A repair remains investigational and is limited to highly selected patients who are prohibitive surgical risks (Isselbacher 2022) (Isselbacher 2022) (Writing Committee 2022) (Isselbacher 2022)πŸ“„.

Complex AAA and TAAA

Planning essentials for complex endovascular repair include careful assessment of sheath access requirements (typically 16–22 Fr), selection of appropriate bridging stents for target vessels (covered or bare-metal based on vessel length and tortuosity), renal protection strategies (hydration, contrast-sparing protocols, and avoidance of nephrotoxic agents), and consideration of staged procedures in extensive 6Thoracic Aortic repairs to reduce spinal cord ischemia risk. Outcomes from experienced centers demonstrate target vessel patency rates typically exceeding 90% at 1–3 years, though endoleak rates remain significant (Type Ia 3–8%, Type II 10–20%) and reintervention rates range from 15–25% at mid-term follow-up. For basic 4Aneurysms repair principles, see 4Chapter 4. (Oderich 2017)πŸ“„ (Oikonomou 2019)πŸ“„

Thoracic Aortic Aneurysm

  • Descending 6Thoracic Aortic: thoracic endovascular aortic repair (TEVAR) is preferred in suitable anatomy, especially in older/high-risk patients; open repair remains for unsuitable anatomy or infection.
  • Ascending/arch: Managed with open or hybrid strategies; branched/fenestrated arch endografts are emerging but limited to select anatomy/centers.
  • Thresholds: Consider repair at β‰₯6.0 cm for descending 6Thoracic Aortic (β‰₯5.5 cm with risk factors) and β‰₯5.5 cm for ascending/arch (lower thresholds with bicuspid valve and risk factors or genetic aortopathy); index to body size in small patients. Connective tissue disorders warrant earlier repair and avoidance of TEVAR when durable proximal/distal fixation is not achievable.
  • LSA management: In TEVAR, intentional LSA coverage may be required; plan revascularization electively when possible to mitigate stroke/SCI/arm ischemia.

Landmark endograft studies and contemporary society guidelines support TEVAR as the preferred approach for many descending thoracic aneurysms in appropriate anatomy, while emphasizing individualized threshold selection and connective tissue disorder considerations. (Dake 1994)πŸ“„ (Szeto 2008)πŸ“„ (Riambau 2017)πŸ“„ (Isselbacher 2022)πŸ“„

Ruptured Thoracic Aortic Aneurysm

  • Ruptured 6Thoracic Aortic: very high early mortality; thoracic endovascular aortic repair (TEVAR) is preferred for descending rTAA when anatomically feasible due to lower perioperative morbidity vs open repair; open repair for unsuitable anatomy, infection, or genetic aortopathy.
  • Technical: Rapid proximal seal; intentional LSA coverage acceptable in emergencies with planned revascularization when indicated; apply spinal cord protection principles as feasible. For vascular trauma management principles, see 16EVTM.

Observational outcomes literature and guideline statements generally favor TEVAR over open repair for ruptured descending thoracic aneurysm when anatomy permits, acknowledging selection bias and the need for rapid hemorrhage control. (Jonker 2010)πŸ“„ (Riambau 2017)πŸ“„ (Erbel 2014)

Thoracic aortic aneurysm thresholds (ascending, arch, descending) and genetic disease considerations

Surgical thresholds for the ascending aorta and arch are generally β‰₯5.5 cm, with lower thresholds in patients with bicuspid valve disease and risk factors or syndromic aortopathy. For the descending aorta, the threshold is β‰₯6.0 cm, though β‰₯5.5 cm may be considered with risk factors or rapid growth. The aortic size index should be used in small patients. Earlier thresholds apply in Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes per guidelines, and natural history data support increasing adverse event risk with larger diameters. (Isselbacher 2022)πŸ“„ (Erbel 2014) (Hiratzka 2010)πŸ“„ (Elefteriades 2002)

Table 6.1. Thoracic Aortic Aneurysm Repair Thresholds

TAAA classification and spinal cord protection bundle

The Crawford classification helps predict spinal cord ischemia (SCI) risk. Major risk factors include extent of coverage, prior 4Aneurysms repair, hypotension, and coverage of the LSA or IMA. A prevention bundle is recommended, including preoperative risk assessment, selective CSF drainage, maintenance of MAP >80–90 mmHg, hemoglobin optimization, LSA revascularization when feasible, and staged procedures. These principles apply to open, thoracic endovascular aortic repair (TEVAR), and BEVAR approaches. (Crawford 1986) (Bischoff 2012) (Estrera 2015)

Crawford Classification of TAAA

Open and endovascular series demonstrate that outcomes are strongly influenced by extent (particularly type II), perioperative hemodynamics, and protocolized spinal cord protection. (Coselli 2016)πŸ“„ (Oderich 2017)πŸ“„

Surveillance After Aortic Dissection

All patients surviving aortic dissection require lifelong imaging surveillance regardless of initial treatment strategy. The dissected aorta remains at risk for late complications including aneurysmal degeneration of the false lumen, new dissection, and disease progression. (Erbel 2014) (Isselbacher 2022)πŸ“„

Surveillance Protocol

Recommended imaging intervals after dissection or thoracic endovascular aortic repair (TEVAR):

  • 1 month: Baseline post-treatment computed tomography angiography (CTA)
  • 3 months: Early follow-up to assess remodeling
  • 6 months: Intermediate assessment
  • 12 months: Annual milestone
  • Annually thereafter: Lifelong surveillance
  • More frequent imaging if concerning features develop (sac growth, new symptoms, endoleak)

These intervals reflect common guideline-based surveillance patterns intended to detect early complications and late aneurysmal degeneration. (Hiratzka 2010)πŸ“„ (Isselbacher 2022)πŸ“„

Favorable Prognostic Indicators

After TEVAR for TBAD, false lumen thrombosis indicates favorable aortic remodeling and is associated with reduced late adverse events. Complete thrombosis of the thoracic false lumen is the goal; persistent perfusion of the false lumen via distal re-entry tears may limit remodeling, and partial thrombosis has been associated with worse outcomes in dissection cohorts. (Nienaber 2013)πŸ“„ (Tsai 2007)πŸ“„

Medical Optimization During Surveillance

Lifelong medical therapy is essential:

  • Blood pressure control (target less than 130/80 mmHg)
  • Beta-blockade to reduce wall stress
  • Statin therapy for cardiovascular risk reduction
  • Smoking cessation (strongly emphasized)

Patients with connective tissue disorders require genetic counseling and family screening. First-degree relatives should be offered imaging surveillance given familial clustering of thoracic aortic disease. (Mac 2022)πŸ“„

References

  1. [1]
    Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022. PMID: 36322642.
  2. [2]
    Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022. PMID: 36322642.
  3. [3]
    Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE. Management of acute aortic dissections. Ann Thorac Surg. 1970;10(3):237-247.
  4. [4]
    DeBakey ME, Henly WS, Cooley DA, Morris GC Jr, Crawford ES, Beall AC Jr. Surgical management of dissecting aneurysms of the aorta. J Thorac Cardiovasc Surg. 1965;49:130-149.
  5. [5]
    Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926.
  6. [6]
    Wahlgren CM, et al. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Vascular Trauma. Eur J Vasc Endovasc Surg. 2025. PMID: 39809666.
  7. [7]
    Wanhainen A, et al. European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases - Editor's Choice. Eur J Vasc Endovasc Surg. 2025. PMID: 41448425.
  8. [8]
    Wanhainen A, et al. European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases. Eur J Vasc Endovasc Surg. 2025. PMID: 41448425.
  9. [9]
    Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): New Insights Into an Old Disease. JAMA. 2000;283(7):897–903.
  10. [10]
    Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease. J Am Coll Cardiol. 2022;80(24):e223-e393.
  11. [11]
    Isselbacher EM et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022. PMID: 36322642.
  12. [12]
    Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022. PMID: 36322642.
  13. [13]
    Writing Committee Members. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023. PMID: 37389507.
  14. [14]
    Writing Committee Members et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease. J Thorac Cardiovasc Surg. 2023. PMID: 37389507.
  15. [15]
    Brunkwall J, Kasprzak P, Verhoeven E, et al. Endovascular repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg. 2014;48(3):285-291.
  16. [16]
    Wanhainen A et al. European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases. Eur J Vasc Endovasc Surg. 2025. PMID: 41448425.
  17. [17]
    Wanhainen A et al. European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Descending Thoracic and Thoraco-Abdominal Aortic Diseases. Eur J Vasc Endovasc Surg. 2025. PMID: 41448425.
  18. [18]
    Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation. 2010;121(13):e266-e369.
  19. [19]
    MacGillivray TE, Gleason TG, Patel HJ, et al. The Society of Thoracic Surgeons/American Association for Thoracic Surgery Clinical Practice Guidelines on the Management of Type B Aortic Dissection. Ann Thorac Surg. 2022;113(4):1073–1092.
  20. [20]
    Matsumura JS, Lee WA, Mitchell RS, et al. The Society for Vascular Surgery Practice Guidelines: management of the left subclavian artery with thoracic endovascular aortic repair. J Vasc Surg. 2009;50(5):1155-1158.
  21. [21]
    Nienaber CA, Rousseau H, Eggebrecht H, et al. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation. 2009;120(25):2519-2528.
  22. [22]
    Nienaber CA, Kische S, Rousseau H, et al. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection (INSTEAD-XL). Circulation. 2013;127(24):2498-505.
  23. [23]
    Tsai TT, Evangelista A, Nienaber CA, et al. Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med. 2007;357(4):349-359.
  24. [24]
    Isselbacher EM et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022. PMID: 36322642.
  25. [25]
    Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146(24):e334-e482. PMID: 36322642.
  26. [26]
    Isselbacher EM, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022. PMID: 36322642.
  27. [27]
    Writing Committee Members, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023;166(1):e1-e157. PMID: 37389507.
  28. [28]
    Writing Committee Members, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023. PMID: 37389507.
  29. [29]
    Writing Committee Members, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023. PMID: 37389507.
  30. [30]
    Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926.
  31. [31]
    Trimarchi S, Nienaber CA, Rampoldi V, et al. Role and results of surgery in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation. 2006;114(1 Suppl):I357-I364.
  32. [32]
    Oderich GS, et al. BEVAR outcomes. *J Vasc Surg*. 2017. PubMed
  33. [33]
    Oikonomou K, et al. ChEVAR outcomes (PERICLES). *J Vasc Surg*. 2019. PubMed
  34. [34]
    Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. N Engl J Med. 1994;331(26):1729-1734.
  35. [35]
    Szeto WY, McGarvey M, Pochettino A, et al. Results of a new surgical paradigm: endovascular repair for acute complicated type B aortic dissection. Ann Thorac Surg. 2008;86(1):87-93.
  36. [36]
    Riambau V, Bockler D, Brunkwall J, et al. Management of Descending Thoracic Aorta Diseases: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53(1):4-52.
  37. [37]
    Jonker FH, Trimarchi S, Verhagen HJ, Moll FL, Sumpio BE, Muhs BE. Meta-analysis of open versus endovascular repair for ruptured descending thoracic aortic aneurysm. J Vasc Surg. 2010;51(4):1026-1032.
  38. [38]
    Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg. 2002;74(5):S1877-S1880.
  39. [39]
    Coselli JS, LeMaire SA, Preventza O, et al. Outcomes of 3309 thoracoabdominal aortic aneurysm repairs. J Thorac Cardiovasc Surg. 2016;151(5):1323-1337.
  40. [40]
    Crawford ES, DeNatale RW. Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease. J Vasc Surg. 1986;3(4):578-582.
  41. [41]
    Estrera AL, Sandhu HK, Charlton-Ouw KM, et al. A Quarter Century of Organ Protection in Open Thoracoabdominal Repair. Ann Surg. 2015;264(5):896-903.
  42. [42]
    Bischoff MS, Brenner RM, Scheumann J, et al. Staged approach for spinal cord protection in hybrid thoracoabdominal aortic aneurysm repair. Ann Cardiothorac Surg. 2012;1(3):325-328.

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

No patient-specific clinical decision support.

Verify clinically relevant information against primary sources and current guidelines.